CAMBRIDGE, Mass., July 21, 2011 /PRNewswire/ — Quanterix
Corporation, an in-vitro diagnostics (IVD) company providing life
science researchers and IVD labs single molecule technology with
unprecedented sensitivity and precision, announced that the
analytical performance of AccuPSA™, a fifth-generation
digital immunoassay for Prostate Specific Antigen (PSA),
demonstrated a robust 2-log improvement in sensitivity over today’s
ultrasensitive third-generation assays for measuring PSA in
patients following radical prostatectomy. The company’s
proprietary Single Molecule Array (SiMoA™) technology
platform combines both digital and analog detection in one
straightforward measurement, thereby broadening the range of
protein detection that can be acquired from a small sample size.
Data will be presented at the American Association for
Clinical Chemistry (AACC) 2011 Annual Meeting held July 24-28 in
Atlanta, GA.
“Because a radical prostatectomy removes the tissue responsible
for producing PSA, measuring this protein in patients following
surgery is very difficult with the assays available today,”
explains David Wilson Ph.D., Senior Director, Product Development
at Quanterix and lead author of the study. “The 1000-fold
improvement in sensitivity from SiMoA enables us to accurately
measure PSA levels in all post radical prostatectomy patients
tested. AccuPSA has the potential to provide precise and
reliable measurements of a patients’ PSA levels post surgery, which
could enable risk stratification for cancer recurrence based on a
single blood test. This test could be a significant advance
for physicians to determine the right treatment and monitoring plan
going forward.”
These data are part of a follow-up retrospective pilot study
conducted by Quanterix that was designed to determine the ability
of the test to predict 5-year biochemical recurrence-free survival
following radical prostatectomy. Data pres
‘/>”/>
